What is Feldan Therapeutics?
Feldan Therapeutics specializes in the development of advanced treatments leveraging a proprietary peptide-based technology for the safe and efficient intracellular delivery of therapeutics. This innovative platform technology is poised to revolutionize the treatment of diseases affecting critical organs such as the lungs and skin. By enabling precise delivery of compounds directly into cells, Feldan aims to unlock novel therapeutic approaches and address unmet medical needs, positioning itself as a key player in the next wave of biopharmaceutical innovation.
How much funding has Feldan Therapeutics raised?
Feldan Therapeutics has raised a total of $34.7M across 3 funding rounds:
Private Equity
$1.2M
Series A
$12.5M
Series B
$21M
Private Equity (2015): $1.2M with participation from Anges Québec
Series A (2018): $12.5M led by GC, Stonebridge Ventures, and Anges Québec Capital
Series B (2024): $21M supported by GC Cell, Genesys Capital, Investissement Quebec, and Fonds de Solidarité FTQ
Key Investors in Feldan Therapeutics
GC Cell
GC Cell Corporation is a South Korean company specializing in cell therapy products and related services, indicating a strategic interest in advanced biological treatments.
Genesys Capital
Genesys Capital is a Toronto-based venture capital firm with a focus on early-stage life sciences and healthcare companies, aligning with Feldan's biopharmaceutical focus.
Investissement Quebec
Investissement Quebec is a provincial financial institution dedicated to supporting business growth and economic development in Quebec, suggesting a regional strategic investment.
What's next for Feldan Therapeutics?
With its recent major enterprise-level funding, Feldan Therapeutics is strategically positioned to accelerate the advancement of its therapeutic pipeline. The capital infusion is expected to fuel further research and development, clinical trials, and the expansion of its operational capabilities. The company's focus on intracellular delivery technology suggests a trajectory towards developing first-in-class treatments, potentially leading to significant breakthroughs in treating complex conditions. This sustained investment underscores a commitment to scaling its operations and bringing its innovative therapies to market, marking a pivotal phase in its corporate journey.
See full Feldan Therapeutics company page
